CVE-2025-64489 json
SuiteCRM: Privilege Escalation via Improper Session Invalidation and Inactive User Bypass
published last yr. modified 4mo ago also EUVD-2025-38349
- cvss
- 8.3
- version 3.1, CNA
- cisa kev
- Not listed
- not in CISA's catalog
- epss
- 0.4%
- EPSS 0.4% chance of exploitation in 30 days, percentile 30%
- public exploits
- 0
- none known
Summary
SuiteCRM is an open-source, enterprise-ready Customer Relationship Management (CRM) software application. Versions 7.14.7 and prior, 8.0.0-beta.1 through 8.9.0 contain a privilege escalation vulnerability where user sessions are not invalidated upon account deactivation. An inactive user with an active session can continue to access the application and, critically, can self-reactivate their account. This undermines administrative controls and allows unauthorized persistence. This issue is fixed in versions 7.14.8 and 8.9.1.
Patch / fix
- suitecrm suitecrm 7.14.8, 8.9.1
Is CVE-2025-64489 in your stack? Fencer shows which of your repositories are affected as soon as an advisory lands, and opens the fix as a pull request.
Check with FencerCISA SSVC
- Exploitation
- none
- Automatable
- no
- Technical impact
- total
- Assessed
- 11mo ago
Exploit prediction
0.36% chance of exploitation in the next 30 days, higher than 30% of all scored CVEs (FIRST EPSS, 2026-11-09).
CVSS scores
| assigned by | version | score | vector |
|---|---|---|---|
| CNA | 3.1 | 8.3 | CVSS:3.1/AV:N/AC:L/PR:L/UI:N/S:U/C:H/I:H/A:L |
| NVD | 3.1 | 8.8 | CVSS:3.1/AV:N/AC:L/PR:L/UI:N/S:U/C:H/I:H/A:H |
Affected products
- SuiteCRM SuiteCRM
Classification
- Weakness
-
- CWE-269 Improper Privilege Management
References
Sources
- CVE List CVE-2025-64489
- NVD CVE-2025-64489
Fencer Intel keeps one entry per vulnerability: the CVE id wins, then GHSA, and records that alias each other are merged, except that two CVEs always keep separate entries. The same data is available as JSON.
CPEs and fixed versions use Anchore's correction of NVD's data: Added CPE configurations because not yet analyzed by NVD.